EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles - ScienceDirect
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered - Gan - 2013 - The FEBS Journal - Wiley Online Library
Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation | EMBO reports
eGFR alto, basso e valori normali
Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors | Future Oncology
Unraveling the differential impact of PAHs and dioxin-like compounds on AKR1C3 reveals the EGFR extracellular domain as a critical determinant of the AHR response - ScienceDirect
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs): Simple drugs with a complex mechanism of action? - Normanno - 2003 - Journal of Cellular Physiology - Wiley Online Library
Epidermal growth factor receptor mutations in lung cancer | Nature Reviews Cancer
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment | British Journal of Cancer
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients | British Journal of Cancer
Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study | PLOS ONE
EGFR-TKIs resistance via EGFR-independent signaling pathways | Molecular Cancer | Full Text
EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles - ScienceDirect
Changes in eGFR and UACR | Download Scientific Diagram
Unveiling mutational dynamics in non‐small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA - Pasini - 2021 - Molecular Oncology - Wiley Online Library
GFR (filtrato glomerulare) - Basso - Salute nella scienza
Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies | Nature Communications
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer - Annals of Oncology
Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer | Experimental & Molecular Medicine
Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries | Molecular Pharmacology
Neuregulin 1–activated ERBB4 as a “dedicated” receptor for the Hippo-YAP pathway | Science Signaling
Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries | Molecular Pharmacology
Genetic alterations shaping tumor response to anti-EGFR therapies - ScienceDirect
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation - Lung Cancer
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies | Oncogene
